Amgen Inc

Day range

$439.07 – $444.59

Open

$444.40

Prev close

$447.28

Volume

2.05M

Market cap

$241.81B

Shares out

540.63M

P/E

27.66

P/S

6.35

P/B

20.69

P/FCF

23.77

ROE

74.8%

ROA

9.1%

Debt/Equity

4.90

Div yield

2.19%

As of Oct 22, 2026

• Security and safetyJul 31, 2026

  In July 2026, Amgen Inc. (the "Company") identified unauthorized activity involving data stored in cloud environments hosted by third-party cloud service providers. The Company has since learned that some of its data, including proprietary data, patient protected health information, and other information, has been exfiltrated from these cloud environments. On July 29, 2026, in connection with our evaluation of the volume of the files that appear to have been impacted and the potential that the types of information in such files could be sensitive, the Company determined that this incident is material.

• Shareholder activismMay 20, 2026

  The stockholder proposal to require an independent board chairman was not approved. For: 72,902,413, Against: 338,465,655, Abstain: 1,571,399.

• Executive leadershipMay 19, 2026

  In order to compensate Mr. Dittrich for foregone equity and incentive compensation at his current employer, he will be granted a one-time RSU award with a value of CHF 4,700,000 that vests 25% per year from the date of grant, and a one-time cash bonus of CHF 4,000,000 as part of his Swiss employment.

• Executive leadershipApr 22, 2026

  On April 22, 2026, Amgen Inc. (the "Company") publicly announced that David M. Reese is retiring from the role of the Company's Executive Vice President and Chief Technology Officer. Dr. Reese will remain employed as an Executive Vice President until his retirement on June 30, 2026.

• Debt activityFeb 19, 2026

  On February 17, 2026, Amgen Inc. (the "Company") issued and sold $1,000,000,000 aggregate principal amount of the Company's 4.200% Senior Notes due 2031, $1,750,000,000 aggregate principal amount of the Company's 4.850% Senior Notes due 2036, $500,000,000 aggregate principal amount of the Company's 5.500% Senior Notes due 2046 and $750,000,000 aggregate principal amount of the Company's 5.650% Senior Notes due 2056. Net proceeds to the Company from the offering were approximately $3,961,495,000, after deducting underwriters' discounts and estimated offering expenses payable by the Company.

• ABBVABBVIE INC.+0.16%
• GILDGilead Sciences Inc-0.73%
• VRTXVertex Pharmaceuticals Inc-2.09%
• AZNAstraZeneca PLC-0.63%
• MRKMerck & Co., Inc.-1.34%
• LLYEli Lilly & Co.-2.54%
• PFEPfizer Inc.-1.28%
• BMYBristol-Myers Squibb Co.-2.41%

Days to cover

4.1

Short interest

14.03M

Avg volume

3.42M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Here's Why Amgen (AMGN) Fell More Than Broader Market
  neutralZacks Investment Research· Oct 23, 2026
• Why Healthcare ETFs Are Hovering Around One-Year Highs
  positiveZacks Investment Research· Oct 23, 2026
• Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy?
  neutralThe Motley Fool· Oct 23, 2026
• Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?
  neutralThe Motley Fool· Oct 22, 2026
• Biotech ETF (BBH) Hits New 52-Week High
  positiveZacks Investment Research· Oct 21, 2026